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Summary 
Regulatable promoter systems allow gene expression to be tightly controlled in vivo. This is highly 
desirable for the development of safe, efficacious adenoviral vectors that can be used to treat human 
diseases in the clinic. Ideally, regulatable cassettes should have minimal gene expression in the “OFF” 
state, and expression should quickly reach therapeutic levels in the “ON” state. In addition, the 
components of regulatable cassettes should be non-toxic at physiological concentrations and should 
not be immunogenic, especially when treating chronic illness that requires long-lasting gene 
expression. In this chapter, we will describe in detail protocols to develop and validate first generation 
(Ad) and high-capacity adenoviral (HC-Ad) vectors that express therapeutic genes under the control 
of the TetON regulatable system. Our laboratory has successfully used these protocols to regulate 
the expression of marker genes, immune stimulatory genes, and toxins for cancer gene therapeutics, 
i.e., glioma that is a deadly form of brain cancer. We have shown that this third generation TetON 
regulatable system, incorporating a doxycycline (DOX)-sensitive rtTA2S-M2 inducer and tTSKid 
silencer, is non-toxic, relatively non-immunogenic, and can tightly regulate reporter transgene 
expression downstream of a TRE promoter from adenoviral vectors in vitro and also in vivo. 
Keywords 
Adenoviral vectors; tetracycline; TetON; inducible; regulatable; gene therapy; doxycycline; glioma; 
Pseudomonas exotoxin A (PE) 
1. Introduction 
Gene expression can be regulated using a promoter that is sensitive to environmental (e.g., 
heat), physiological (e.g., steroids), or chemical (e.g., tetracycline) changes in the body (1–3). 
In general, chemical switches are preferable to either physiological or environmental switches 
because pharmacokinetic/pharmacodynamic properties can be determined, reducing the 
fluctuations that may otherwise interfere with environmental or physiological regulators. An 
ideal regulatable system for gene therapy requires that the following conditions are met: (1) 
regulation of gene expression in vivo should be achievable using a compound that is nontoxic; 
(2) the compound must be able to penetrate into the desired target tissue or organ at effective 
concentrations; (3) it should have a half-life of a few hours (as opposed to minutes or days), 
so that when withdrawn or added (depending on the regulatable system used), gene expression 
can be turned on or off quickly and effectively; (4) the genetic switches employed should ideally 
be non-immunogenic in the host; (5) expression in the “OFF” state should be minimal, and 
expression in the “ON” stale should be sufficiently high for therapeutic efficacy of the transgene 
(4). We have developed a regulatable cassette based on the TetON system (see Note 1). In this 
cassette, therapeutic or reporter transgenes are under the control of the TRE promoter (5). The 
Methods Mol Biol. 2008;434:239-66. 
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Tet-sensitive transactivator, rtTA2S-M2 (see Note 2) (6,7), and the repressor element tTSkid 
(8) are both constitutively expressed by a murine CMV promoter. In the “OFF” state, tTSkid 
suppresses unwanted activation of TRE and lowers basal therapeutic gene expression (9). In 
the “ON” state doxycycline (DOX) (a water soluble Tet analog that can be administered in 
food and water) binds with the rtTA2S-M2 transactivator, inducing a conformational change 
in rtTA2S-M2 that confers binding affinity for TetO repeat elements present in the TRE 
promoter, thus inducing expression of genes downstream from the TRE promoter (see Fig. 1). 
Tet regulatable vectors have been used in our laboratory for inducible expression of therapeutic 
transgenes in vitro (10) and in vivo (11). These Tet-dependent regulatable expression systems 
constitute an ideal platform to develop vectors that will allow regulated transgene expression 
for both basic and translational research applications and also to generate vectors expressing 
genes that could be toxic to the producer cell line, i.e., FasL, TNFα, Pseudomona exotoxin A, 
Diphteria toxin. In this chapter, we will describe in detail the protocols our laboratory has 
successfully used for (1) cloning plasmids containing transgenes under the control of the TetON 
regulatable cassette; (2) cloning mammalian expression plasmids where transgene expression 
is tightly regulated by the TetON promoter; (3) validation of cloning by Southern blot; (4) 
scale-up of HC-Ad vectors; (5) confirming DOX-inducible gene expression in vitro; and (6) 
in vivo. 
2. Materials 
2.1. Cloning of Tet-ON Regulated Plasmids 
1. Plasmids (see Table 1 for description and sources). 
a. pΔE1sp1A. 
b. pAL120. 
c. pIRES-tTSkid-pA. 
d. pUHS 6-l. 
e. 
f. 
g. 
pIRES. 
pUHrT 62-l. 
prtTA2S M2-IRES-tTSkid -pA. 
h. pSP72Bgl2. 
i. 
j. 
pSP72-mCMV. 
pSP72[mCMV-rtTA2S M2-IRES-tTSkid -pA]. 
k. pBS2 SK(+) [Tre-MCS-pA]-Kana. 
2. 
3. 
4. 
5. 
6. 
Restriction endonucleases (REs) and REs buffer (NEB, Ipswich, MA, USA). 
1% Agarose gel: 1% w/v agarose in 0.5× TBE buffer, 300 ng/ml ethidium bromide. 
Gel Purification Kit (available from Qiagen, Valencia, CA, USA). 
T4 DNA ligase and ligase buffer. 
Maxi Prep kit (Qiagen). 
2.2. Generation of pmCMV-TetON Plasmid Driving Inducible Expression of Gene of Interest 
1. Plasmids (see Table 1 for description and sources). 
a. pmCMV-TetON. 
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b. pSP72Bgl2-MCS. 
2. REs and buffer; Swa1, Bcl1, Afl2 or Age1. 
Calf intestinal phosphatase (CIP) (NEB) 
1% Agarose gel: 1% w/v agarose in 0.5× TBE buffer, 300 ng/ml ethidium bromide. 
Gel documentation system. 
UV light box. 
Gel Purification Kit (available from Qiagen). 
Quick Ligase and Ligase buffer (NEB). 
Maxi Prep kit (Qiagen). 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. Luria–Bertani media (LB): LB + 50 μg/ml Ampicillin (LB-AMP), LB-AMP agar 
    plates (12). 
2.3. Confirming Insertion of Transgene by Southern Blot 
1. 
2. 
3. 
4. 
5. 
6. 
0.25 M HCl (500 ml). 
0.4 M NaOH(1 l). 
Tris–HCl pH 9.00 (500 ml). 
Tris–HCl pH 8.00 (500 ml). 
20× SSC: 3 M NaCl, 0.3 M Na-Citrate, pH 7.0. 
Pre-hybridization solution (5× SSC): 1% blocking reagent, 0.1% N-lauroylsarcosine, 
0.02% sodium dodecyl sulfate (SDS), heat to 60°C for 30 min or until fully dissolved. 
Store at −20°C. 
Buffer 1: 100 mM Tris–HCl, 150 mM NaCl, pH 7.5. 
Buffer 2: 100 mM Tris–HCl, 150 mM NaCl, 1% Blocking reagent (Roche, 
Indianapolis, IN, USA), pH 7.5. 
Buffer 3: 100 mM Tris–HCl, 150 mM NaCl, 50 mM MgCl2, pH 9.5. 
7. 
8. 
9. 
10. Buffer 4: 10 mM Tris–HCl, 1 mM EDTA, pH 8.0. 
11. Color substrate: 200 μl NBT/BCIP in 10 ml Buffer 3 (see step 9). 
2.4. Scale-up of HC-Ad Vector Expressing Transgene Regulated by Tet-ON 
1. 
2. 
293 FLPe cells (293 cells stably transfected with Flippase expressing (FLPe) 
recombinase were generated by our laboratory (13)). 
293 FLPe medium: 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA), 1% 
non-essential amino acids (Gibco), 1% L-Gln (Gibco), 10 IU/ml Penicillin– 
Streptomycin (Gibco), 1.5 μg/ml Puromycin (Sigma, St. Louis, MO, USA). 
First-generation FLPe-sensitive helper adenovirus (FL helper) (generated by our 
laboratory (13)). 
pSTK120 plasmid with TetON regulatable cassette driving transgene expression (see 
Table 1 for description and sources). 
Ultracentrifuge (Beckman Coulter, Fullerton, CA, USA). 
5% sodium deoxycholate in H2O. 
3. 
4. 
5. 
6. 
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7. 
8. 
2 M MgCl2. 
3-ml sterile syringe (Becton Dickenson, Franklin lakes, NJ, USA). 
5-ml sterile syringe (Becton Dickenson). 9. 
10. 18-G, 3.5-inch spinal needle (Becton Dickenson). 
11. 21-G, 1′-long needle (Becton Dickenson). 
12. 1.33 g/ml = 8.349 g CsCl dissolved in 16 ml CsCl buffer. 
13. 1.45 g/ml = 8.349 g CsCl dissolved in 11.4 ml CsCl buffer. 
14. CsCl buffer: 5 mM Tris–HCl, pH 7.5, 1 mM EDTA, pH to 7.5 with 1 M sodium 
    hydroxide, and then filter sterilize using a 0.45-μm filter. 
15. TE buffer: 10 mM Tris–HCl, 1 mM EDTA, pH to 7.8 with 1 M sodium hydroxide, 
    and then sterilize by autoclaving. 
16. Mineral oil. 
17. Buffer A: 7.092 g Tris–HCl, 0.4284 g MgCl2, 35.5 g NaCl, in 4.5 l total volume with 
    H2O and autoclaved. 
18. Buffer B: Buffer A with 10% glycerol and sterilized by autoclaving. 
2.5. Confirming Inducible Gene Expression in Vitro 
1. Cell lines. 
a. Cos7 (ATCC) African Green Monkey SV40-transfected kidney fibroblast 
cell line. 
b. GL26 (ATCC) C57BL/6 mouse glioma cell line. 
c. CNS1 (ATCC) Lewis rat glioma cell line. 
d. U87 MG (ATCC) human, caucasian female 44 years old; glioblastoma- 
   astrocytoma. 
e. 
f. 
g. 
2. 
3. 
U251 (ATCC) human glioma cell line. 
IN859 (human biopsy primary culture obtained by our laboratory (14)). 
IN2045 (human biopsy primary culture obtained by our laboratory (14)). 
DOX (Sigma). 
Culture media; MEM media (Gibco) containing 10% FBS (Gibco), 1 mM L-Gln 
(Gibco), 1mM non essential amino acids (Gibco), 10 IU/ml Penicillin/Streptomycin 
(Gibco). 
ELISA specific for transgene (Flt3L ELISA from R&D Systems, Minneapolis, MN, 
USA). 
Immunoglobulins specific for Flt3L (generated in our laboratory (15)), PE toxin 
(generated in our laboratory), IL4 (R&D). IL13 (R&D), and IL13-alphaR2 (R&D). 
Immunoglobulins specific for β-galactosidase (generated in our laboratory (15)). 
Secondary anti-Ig-specific immunoglobulins-HRP conjugated (Dako Cytomation, 
Glostrup, Denmark). 
SDS–PAGE equipment (BioRAD). 
4. 
5. 
6. 
7. 
8. 
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9. RIPA Lysis buffer: 50 mM Tris–HCl, pH 7.4 (50 μl of 1 M Stock), 150 mM NaCl 
(30 μl of 5 M Stock), 1 mM NaF (20 μl of 50 mM Stock), 1 mM NaVO4 (8 μl of 125 
mM Stock), 1 mM EGTA, pH 8.0 (20 μl of 50 mM Stock), 1% NP40 (10 μl), 0.25% 
sodium deoxycholate (25 μl), 1× PI (1 μl of 1000× Stock), 1× PMSF (1 μl of 1000× 
Stock), made up to 1 ml with 831 μl dH2O. 
10. Mini Trans-blot cell for Western Blotting (BioRad, Hercules, CA, USA). 
11. PowerPac 300 Power supply (BioRad). 
12. Film and automated film developing machine (Kodak, Rochester, NY, USA). 
2.6. Confirming Inducible Gene Expression in Vivo 
1. 
2. 
3. 
4. 
Male Fisher rats, 200–250 g (Harlan Sprague Dawley). 
DOX (Sigma). 
Stereotactic apparatus (Stoelting). 
Anesthetics and analgesics. 
a. 100 mg/ml Ketamine HCl (Phoenix Pharmaceuticals Inc., St. Joseph. MO, 
USA). 
b. 1 mg/ml Medatomidine HCl (Pfizer, Exton, PA, USA). 
c. 0.3 mg/ml Buprinorphine (Reckitt Benckiser, Richmond, VA, USA). 
d. 5 mg/ml Atipamazole HCl (Pfizer). 
5. 
6. 
First generation Ad and HC-Ad vectors. 
Surgical equipment. 
a. Scalpel and sterile blades. 
b. Surgical Scissors, 14-cm long, straight, Sharp (World Precision Instruments, 
   Sarasota, FL, USA). 
c. Iris Forceps, 10-cm long, serrated straight 0.8-mm tips (World Precision 
Instruments). 
d. Wire Retractors, 5-cm long, 15-mm wire blades, maximum spread 25 mm 
   (World Precision Instruments). 
e. 
f. 
7. 
8. 
9. 
Nylon Ethicon Sutures 3-0 (Cardinal Health, Dublin, OH, USA). 
Dremel Stylus cordless drill and drill bits (Dremel, Racine, WI, USA). 
26-G, 10-μl Hamilton needle and syringe. 
Tyrode's solution: 0.14 M NaCl, 1.8 mM CaCl2, 2.7 mM KCl, 0.32 mM NaH2PO4, 
5.6 mM glucose, and 11.6 mM NaHCO3. 
4% Paraformaldehyde (w/v) in PBS. 
10. PBS + 0.1% sodium azide. 
11. Electronic VT1000S vibrating blade vibratome (Leica, Wetzler, Germany). 
12. Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA, USA). 
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3. Methods 
3.1. Cloning of Tet-ON Regulated Plasmids 
1. We have generated both Ad (TetOFF or TetON) and HC-Ad (TetON) vectors 
expressing inducible transgenes using Tet-regulatable system (5,16,17). Because of 
genomic size constraints (up to 7 kb can be inserted into first generation, E1a/E4 
deleted viruses), first-generation Ad vectors require the Tet-regulatable cassette to be 
expressed by one adenoviral vector, and the transgenes under the control of the TRE 
promoter to be expressed by another vector. Thus, inducible gene expression in cells 
requires co-infection with Ad vectors expressing Tet-regulatable elements and Ad 
vectors expressing TRE-driven transgene elements. High multiplicity of infection 
(MOI) can be used in vitro, and first-generation Ad vectors are relatively easy to scale 
up, thus Ad vectors are useful for in vitro or in vivo studies of transgene biological 
activity or preclinical efficacy. The latest generation, high capacity, gutless Ad vectors 
(HC-Ad), with a theoretical capacity of ∼35 kb, can encode for Large transcriptional 
units, and transgene expression form of these vectors is stable even in the presence 
of a peripheral anti-Ad immune response as could be encountered in patients 
undergoing clinical trials. They are therefore the preferred choice for pre-clinical in 
vivo studies (13). Here we will describe in detail the generation of HC-Ad vectors; 
first-generation Ad vectors can also be generated by excising either TetON or Tre- 
transgene-pA elements and inserting them into first-generation Ad shuttle plasmids 
(e.g., pΔE1sp1A or pAL120). 
To generate the TetON cassette, the transcriptional silencer carrying plasmid p[IRES- 
tTSKid-pA] was generated by digesting pUHS 6-1 with Xba1 and Hind3 to liberate 
tTSkid, ligating tTSkid into the shuttle plasmid pΔE1sp1A and digesting with Xba1 
and Sal1 before ligation into pIRES digested with Xba1 and Sal1. This generated a 
plasmid containing IRES followed by tTSkid and a polyAdenylation (pA) signal. 
The rtTA2SM2 transactivator was excised using EcoRI and BamHI from plasmid 
pUHrT 62-1; the BamHI site was adapted using short oligonucleotide dimers to add 
an Mlu1 restriction site. The adapted rtTA2SM2 insert was directionally cloned into 
a previously generated plasmid p[IRES-tTSKid-pA], digested with EcoR1 and Mlu1, 
resulting in intermediate plasmid, p[rtTA2SM2-pIRES-tTSKid-pA]. This generated 
a plasmid where the rtTA2SM2 and tTSkid coding sequences were separated by an 
IRES (5). 
Next, we placed a constitutive mCMV promoter upstream or rtTA2SM2 to drive 
expression of rtTA2SM2 and tTSkid. We excised the mCMV promoter from pAL120 
with EcoRI and HindIII and ligated into a pSP72-Bgl2 shuttle vector (Clontech, 
Mountain View, CA, USA), producing intermediary plasmid pSP72[mCMV]. 
Plasmid p[rtTA2SM2-pIREStTSKid-pA] was excised with XhoI and SalI to release 
cassette [rtTA2SM2-pIRES-tTSKid-pA] and subsequently cloned into its 
corresponding sites into plasmid pSP72[mCMV], generating the intermediate 
plasmid pSP72[mCMV-rtTA2SM2-pIRES-tTSKid-PA]. 
The [mCMV-rtTA2SM2-pIRES-tTSKid-pA] regulatable Tet-ON cassette was then 
excised with BgIII and cloned into the BgIII site of intermediate plasmid pBlueScript 
II SK(+)[TRE-MCS-polyA]-Kanamycin, thus generating the final intermediate 
plasmid, pBlueScript II SK(+)[TRE-MCS-polyA]-[mCMV-rtTA2SM2-IRES- 
tTSKid-pA]-Kanamycin. 
The MCS contains REsites for Bcl1, Afl2, Age1, and Swa1 and can be used to directly 
insert transgenes downstream of TRE. A shuttle vector, pSP72-Bgl2-MCS, also exists 
that facilitates the cloning of transgenes into pmCMV-TetON. 
2. 
3. 
4. 
5. 
6. 
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3.2. Generation of pmCMV-TetON Plasmid Driving Inducible Expression of the Gene of 
Interest 
1. Digest 1 μg pmCMV-TetON (see Note 3) and 1 μg pSP72-Bgl2-MCS containing the 
transgene with compatible restriction enzyme (Swa1, Bcl1, Afl2, or Age1). Thy 
reaction mixture should contain 10 μl 10× RE buffer (see Note 4), 1 μg DNA, 5 μl 
RE, and H2O bringing entire volume to 100 μl and needs to be digested at 37°C (55° 
C for Bcl1) for at least 2 h. This will linearize the pmCMV-TetON plasmid and drop 
out the transgene with compatible ends, allowing the ligation of the therapeutic gene 
downstream of the TRE promoter and upstream of pA sequence. 
Digestion must be to completion, confirm that no undigested DNA remains by running 
a 1% agarose gel with 5 μl reaction mixture (and undigested DNA as a control in 
another gel lane) before continuing. 
Run the entire sample on a 1% agarose gel and use a new razor blade to cut out the 
band of interest from the gel, visualizing the DNA using a UV illumination source 
(see Note 5). 
Purify the DNA from Agarose gel using DNA purification columns from Qiagen. 
Elute the DNA in 30 μl TE buffer, and run 2 μl on an agarose gel to quantify DNA 
concentration. 
Dephosphorylate the ends of the vector using CIP. This prevents religation of vector. 
Set up the ligation reaction with (10 min, room temperature) Quick Ligase (NEB). 
We generally ligate 200 ng vector with a threefold molar excess of insert. 
Transform competent DH5α cells with ligated product (use 5 μl ligation reaction) and 
culture overnight at 37°C or Agar plates with LB + Ampicillin (50 μg/ml). 
Pick colonies and grow for 8 h at 37°C in 2 ml LB + Ampicillin (50 μg/ml). 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. Transfer 1–200 ml LB + Ampicillin (50 μg/ml) and grow overnight at 37°C. 
11. MAXI prep DNA from bacteria and use REs to confirm that the transgene has been 
    inserted in the correct orientation. Expression of the transgene can be verified here 
    by transient transfection before proceeding to insert the cassette into pSTK120 vector. 
3.3. Confirming Insertion of Transgene by Southern Blot 
1. Probe preparation: Digest 5–10 μg of plasmid DNA containing the sequence of 
preference (e.g., IL13) to liberate the probe. (10 μl DNA, 10 μl Buffer, 5 μl RE, 75 
μl H2O). Digest for 2 h at 37°C and run 1 μl to check completion of the digestion, 
together with undigested DNA and DNA ladder (Bioline Hyperladder I). Gel extract 
the desired fragment using Qiagen Gel Extraction kit in 30 μl total of milliQ water. 
Sample preparation: Nucleic acids absorb strongly at 260 nm. The optical density at 
260 nm (OD260) of DNA samples (RNA free) can be measured using 
spectrophotometry to determine the concentration of DNA in a sample. Other major 
components of cells, i.e., proteins, lipids, etc., do not absorb strongly at 260 nm. Dilute 
1 μl plasmid DNA with 100 μl H2O, transfer to a quartz cuvette, and determine the 
OD260 after first blanking the machine with H2O only. The concentration of DNA 
can be calculated by multiplying the OD260 of each sample by 5000 (Concentration 
will be μg/ml DNA). Digest 1 μg plasmid DNA with a restriction enzyme that drops 
out a band containing the DNA sequence (1 μg plasmid DNA; 3 μl HindIII; 2 μl Buffer 
2; H2O up to 20 μl). Incubate at 37°C for 2 h and run 1 μl to check that the digestion 
has proceeded to completion. 
2. 
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3. Gel Electrophoresis: Run DNA ladder, and Plasmid DNA in a 0.8% agarose gel at 
95 V (Biorad, Minisub-cell GT; Biorad, PowerPac 300), for 1 h. Take a photograph 
of the gel using a gel documentation system (Alpha Innotech Corporation). 
Transfer: Use a positively charged membrane to bind negatively charged DNA 
(Roche). Rinse the membrane with MilliQ water and soak in 0.25 M HCl, 15–39 min. 
Rinse the membrane twice with MilliQ water then soak in 0.4 M NaOH. Rinse with 
MilliQ water and set up the transfer apparatus. Trim off the edges of the gel that do 
not contain DNA, including the wells. Cut the top right corner of the gel with a blade 
(this will allow the orientation of the gel to be determined later). Cut thick Whatman 
3 M filter paper with the exact measures of the gel. Cut the membrane to the same 
size as the gel and filter paper. Soak filters and membrane in 0.4 M NaOH and cut a 
piece of filter paper (Whatman, 3 M) long enough to form the “bridge” over the tray 
(Life Technologies, Blot transfer system 20–25). Place the Whatman filter paper 
bridge on the Blot transfer system with the ends immersed in 0.4 M NaOH. Place the 
gel on this bridge and place the membrane above it taking care not to leave any bubbles 
between the gel and the membrane (see Note 6). Put the thick filter paper and paper 
towels on top of the membrane and place the weight on top of the paper towels. 
Transfer overnight. 
Labeling the probe: [Note; 10 ng to 3 μg of DNA can be labeled (Roche, DNA labeling 
and detection kit).] Add 1 μg the DNA and MilliQ water to a final volume of 16 μl. 
Take OD260 of the purified probe and calculate the volume needed for 1 μg of DNA. 
Denature the diluted probe DNA in a boiling water bath for 10 min and quickly transfer 
to ice. Add the rest of the reagent needed For the labeling reaction (2 μl 
Hexanucleotide Mix 10×; 2 μl dNTPs labeling mix; 1 μl Klenow enzyme). Vortex, 
spin down and incubate overnight at 37°C a longer incubation will increase the yield 
of the labeled DNA. Stop the reaction by adding 2 μl of 0.2 M EDTA; pH 8.00 and 
precipitate labeled DNA with 2.5 μl of 4 M LiCl and 75 μl 100%EtOH. Mix well and 
leave 2 h at −20°C, centrifuge 15 min 15,000 g rinse the pellet with 50 μl of 70% ice 
cold EtOH, dry and resuspend the labeled pellet in 50 μl of MilliQ water. Store at 
−20°C until use. 
Prehybridization: Briefly soak the membrane in 5× SSC buffer and transfer the 
membrane to a hybridization tube (TECHNE, FHB11). Prepare the prehybridization 
solution (10 ml/membrane) (15 ml 5× SSC; 150 mg blocking reagent (Roche DNA 
labeling and detection kit); 15 mg 0.1% N-lauril sarcosine and 3 μl 10% SDS). 
Incubate for 30 min at 65°C, until dissolved, add 10 ml of prehybridization solution 
taking care of avoiding air bubbles, again with the help of a pipette and incubate for 
2 h, at least, at 68°C. 
Hybridization: Denature the probe by heating for 10 min at 95°C and transfer to ice 
immediately. Remove the membrane from the incubator and add the 50 μl of labeled 
probe to the prehybridization solution. Incubate at 68°C overnight. Remove the 
membrane from the cylinder and wash in 2× SSC/0.1% SDS at room temp. 15 min 
on a shaker. Change washing solution to 0.2× SSC/0.1% SDS, incubate at room 
temperature, 15 min on a shaker and wash once with 0.1× SSC/0.1% SDS at 65°C, 
30 min. 
Immunodetection: [Note: all the washes are done while shaking.] Wash the membrane 
in buffer 1, for 1 min and incubate the membrane for 30 min in buffer 2. Wash the 
membrane with buffer 1 for 5 min, then dilute 4 μl of anti-digoxigenin/Alkaline 
Phosphatase conjugate (vial 8, provided in the kit) in 10 ml of buffer 1 add to the 
membrane and incubate at room temperature, 30 min while shaking. Wash with buffer 
1, for 30 min and incubate in buffer 3 for 2 min. Transfer the membrane to the color 
4. 
5. 
6. 
7. 
8. 
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substrate solution (10 ml buffer 3 + 200 μl NBT/BCIP). Incubate in the dark until the 
bands are clearly visible and then stop the reaction using buffer 4. This incubation 
can be prolonged until bands are evident. Archive the image using a scanner or a gel 
documentation system. The image can be compared with the original agarose gel to 
determine sizes of the DNA (see Fig. 2 as an example). 
3.4. Scale up of HC-Ad Vectors Expressing Transgenes Regulated by TetON 
1. The generation of first-generation Ad vectors has been described in great detail before 
(18). Here we will focus on the production and generation of HC-Ad vectors 
containing the TetON regulatable cassette. 
The entire cassette encoding the transgene regulated by TRE promoter and the TetON 
cassette expressed by mCMV must be transferred into a plasmid that will allow 
production of adenoviral particles. We use pSTK120 to generate high-capacity Ad 
vectors. pSTK120 is a large plasmid that does not contain any known genes or 
regulatory sequences and is relatively stable; recombination events are low compared 
with other large plasmids. pSTK120 contains Amp resistance and also contains Ad-5 
LTR sequences and the packaging sequence (Ψ), allowing production of HC-Ad 
vectors. pSTK120 is ∼28 kDa but can be reduced in size if necessary by digestion 
with RE (e.g., Nhe1 and Nar1 can each remove 3 Kb from the final plasmid). Inserts 
can be cut with Eag1 compatible enzymes (e.g., Notl), or Nhe1 compatible enzymes 
(e.g., Avr2) (see Table 2 for the complete list of pSTK120 plasmids and cloning 
capacities). 
The insert [TRE-hsFlt3LpolyA]-[mCMV-rtTA2SM2-pIRES-tTSKid-pA]-Kana was 
excised from the shuttle plasmid using NotI and cloned into the compatible EagI site 
of HC-Ad plasmid pSTK120.2, generating pSTK120.2-[TRE-hsFlt3L-polyA]- 
[mCMV-rtTA2SM2-pIRES-tTSKid-pA]-Kana (HC-Ad-mCMV-TetON-Flt3L). The 
fragments were ligated overnight, transformed into DH5α cells, and plated on LB 
plates with 25 μg/ml kanamycin (12). Plasmids were isolated from overnight cultures 
using miniprep and screened by HindIII digestion. Maxiprep purifications were 
performed on the correct clones (Qiagen). Restriction enzymes were used to confirm 
the integrity of the plasmids (see Note 7). 
The major steps in HC-Ad vector production are rescue, amplification, scale up, and 
purification of HC-Ad vectors as previously described (19). For a summary of this 
protocol (see Fig. 3). 
Rescue: Seed 2 × 106 293 FLPe cells (seeNotes 8 and 9) into 60-mm dish the day 
before transfection. (Note: 293 cells FLPe cells grow in MEM with puromycin 1.5 
μg/ml). Transfect the 293 FLPE cells (80% confluent cells) with 10 μg of gutless 
plasmid DNA linearized with PmeI, using the calcium phosphate precipitation 
technique (seeNote 10). Incubate the cells at 37°C, 5% CO2. (Include one flask 
transfected with pMV12, a plasmid expressing β-galactosidase as a transfection 
positive control, and another flask transfected with no plasmid DNA as a transfection 
negative control.) Sixteen hours later, wash the 293 FLPe cells first with PBS and 
second with 293FLPe culture media. Infect the cells with helper virus at an MOI 5 
diluting the virus in 5 ml of medium. Incubate at 37°C, 5% CO2. Harvest the cells 
when full CPE appears (usually 2–3 days). Tap the side of the dish to dislodge the 
cells (or use scraper) and lyse the cells by three freezing and thawing cycles. 
Amplification: For each amplification passage (P1 to P6), seed 293 FLPe cells into a 
60-mm dish the day before infection to obtain approximately 80% confluence of cells 
the next day. Cells are grown and incubated at 37°C, 5% CO2. Infect using 10% of 
the volume collected from the previous passage lysate and coinfect with FL helper 
2. 
3. 
4. 
5. 
6. 
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vims at MOI = 1. Harvest the cells when full CPE appears. Tap the side of the dish 
to dislodge the cells (or use scraper) and lyse the cells by three freezing and thawing 
cycles. 
7. Scale-up: For P7, seed a 150-mm dish with 1 × 107 cells and infect using 100% of 
the lysate from P6 and co-infect with FL helper virus at MOI = 1. Keep 10% of the 
lysate (usually 50–100μl), for analysis, BFU, IU, molecular titration by duplex RT– 
PCR (18). Harvest the cells when full CPE appears and pellet down the cells by 
centrifugation. 10 min at 1500 g, 4°C; and resuspend in 500 μl of PBS. Seed 30 dishes 
(150 mm) with 1 × 107 cells the day before infection. Prepare the medium by adding 
the viral vector suspension and the FL helper virus at MOI 1, and infect the cells. 
Harvest the cells when full CPE appears (2–3 days) pellet down the cells by 
centrifugation 10 min at 1500 g, 4°C; and resuspend in 8 ml of 100 mM Tris–HCL 
pH 8.0. Store at −80°C until CsCl purification is performed. 
We have also used a similar method for rescuing and scaling up of HC-Ad vectors 
developed by Philip Ng and colleagues that utilizes a Cre recombinase sensitive helper 
adenovirus to package HC-Ad genomes in trans (19,20). We have found that this 
method, allows larger number of cells to be infected in the final scale-up step; thus, 
we routinely achieve higher titers (∼one log higher titer) of HC-Ad vectors using the 
Cre method. This method has been described in detail by Ng et al. (19). 
Purification: Cesium chloride (CsCl) purification has been described before for the 
purification of first generation adenoviral vectors (13,19). Briefly, 4 ml of 5% sodium 
deoxycholate is added to the cell pellets and incubated at room temperature for 30 
min to lyse the cells. Add 400 μl of 2 M MgCl2 and 100 μl of DNaseI. Incubate at 
37°C for 1 h to remove genomic and non-packaged Ad DNA. Centrifuge at 20,000 × 
g for 15 min. Pipette 2.5 ml of CsCl at a density of 1.33g/ml in a Beckman 14-ml 
centrifuge tube (Beckman, 331374) (to fit a SW40 swing bucket rotor). Then, using 
a 5-ml syringe equipped with a wide bore 18-G needle, place the needle at the bottom 
of the centrifuge and very slowly inject 1.5 ml of CsCl at a density of 1.45 g/ml, so 
the less dense layer floats on top of the denser layer. (Densities were calculated by 
the determination of the refractive index.) CsCl was dissolved in 5 mM Trizma HCl, 
1 mM EDTA pH 7.8. Overlay 7 mL of the virus solution on the CsCl gradient. Overlay 
mineral oil on the viral layer until the meniscus reaches 2 mm from the top of the 
tube. Place the tubes in the centrifuge buckets SW40Ti (Beckman Coulter) and seal 
before leaving Class 2 hood. Weigh a set up balance tube to an identical weight (±0.02 
g) before placing tubes in rotor and centrifuge in an ultracentrifuge for 2 h at 90,000 
× g (22,500 rpm for the SW40 rotor). Remove tubes from the rotor in the Class 2 
hood. Puncture side wall approximately 1 cm below the level of the band with a wide 
bore 21-G syringe needle. This will allow you to get a large enough angle to remove 
the entire viral band. The viral band is the lowest of the three bands that should be 
visible. The volume is NOT important at this step. Dilute the virus fraction with half 
a volume of TE pH 7.8. Layer the virus fraction on top of a second CsCl gradient 
prepared with 1 ml of 1.45 g/ml CsCl and 1.5 ml of 1.33 g/ml CsCl. Overlay mineral 
oil until the meniscus is 2 ml from the top of the tube and centrifuge in an 
ultracentrifuge for 18 h at 100,000 × g (23,800 rpm for the SW40 rotor). Recover the 
viral band as before (see Note 11). At this stage, the volume recovered is very 
important. Inject virus into a dialysis cassette and dialyze the banded virus twice 
against 1.5 l of Buffer A for 2 h and once against 1.5 l of Buffer B for 2 h at room 
temperature. Aliquot the virus and store at −70°C. Maintain sterility at all times. 
8. 
9. 
10. Titration of HC-Ad vectors is usually performed by measuring the total viral particles 
    using Optical Density (see Note 12). 
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11. In vitro and in vivo assessment of gene expression must be carried out before assessing 
    the therapeutic efficacy of the vector in preclinical models (see Note 13). 
3.5. Confirming Inducible Transgene Expression in Vitro 
1. In vitro expression can be confirmed using ELISA, immunocytochemistry, or 
Western blotting (seeNote 14). It is preferable to use more than one method to confirm 
expression in vitro before proceeding. In this example, we tested HC-Ad-mCMV- 
TetON-Flt3L for transgene expression in the presence and absence of Dox by ELISA 
and by immunocytochemistry. We tested Ad-IL4-TRE-IL-13.PE for expression by 
immunofluorescence and bioactivity by the production of cytotoxic IL13.PE (see 
Note 15). 
ELISA: Flt3L is a secretable protein: we measured Flt3L expression in the media of 
HC-Ad-infected glioma cells from mouse, rat, and human in the presence and absence 
of Dox. Cells were plated in 12-well plates at 50,000 cells (GL26: CNS-1; U251; U87 
MG; IN859; IN2045) per well and allowed to adhere overnight. The following 
morning, media was replaced with 0.5 ml of media containing DOX (1 μg/ml) or 
without DOX and cells were then infected with HC-Ad-TetON-Flt3L (50,000 VP/ 
CELL). After 72 h, Flt3L (transgene) was determined in the cell culture supernatant 
using ELISA (R&D Systems), exactly as outlined in the manufacturer's guide (see 
Note 16). Inducible expression of Flt3L was detected in the media by ELISA after 
six glioma cell lines were infected with HC-Ad-TetON-Flt3L and incubated with or 
without Dox (see Fig. 4). 
Immunocytochemistry: GL26, CNS-1, U251, U87, IN859, and IN2045 cells were 
seeded in 12-well dishes (50,000 cells/well), on sterile coverslips, and allowed to 
adhere overnight. The following day, cells were incubated with 1 μg/ml DOX or 
without and were infected with HC-Ad-mCMV-TetON-Flt3L (50,000 VP/Cell). 
After 72 h, cells were washed cells two times with PBS and fixed for 10 min in 4% 
PFA at room temperature. Cells were then blocked (1 h, room temperature) with 10% 
Horse Serum in TBS + 0.5% Triton-X100. Stain 2 h with primary antibody (against 
transgene), use the dilution recommended by the manufacturer. Wash the cells and 
stain with secondary antibody (these can be either fluorescent tagged or Biotin 
tagged). If using biotinylated secondary Ab, incubate for 1 h, wash with PBS three 
times and add avidin-HRP (1:1000 in PBS, 1 h, room temperature). Wash in PBS, 
wash two times in 100 mM sodium acetate, and stain with DAB. Allow precipitate to 
develop (usually 1–5 min), wash with sodium acetate and then with PBS + 0.1% 
sodium azide. Mount on slides and visualize gene expression using visible light 
microscopy (see Fig. 4) (see Note 17). 
Western blotting: Lyse cells in RIPA buffer and quantify protein concentration of cell 
lysates. For each sample dilute 30 μg of the ceil lysate in 20 μl total volume in SDS– 
Tris buffer containing DTT. Boil samples for 10 min to denature proteins. Run 30 
μg samples on an SDS–polyacrylamide gel (with protein standard markers) and 
transfer to nitrocellulose membrane (Amersham Biosciences). Block membranes and 
incubate with primary and secondary antibodies as recommended by the 
manufacturer. We use our custom Flt3L antibody at 1:1000 in blocking solution [TBS 
+ 0.05% Tween20 (TBS-T) with 5% dry milk powder] overnight at 4°C on 
membranes blocked previously for I h with blocking solution. Membranes are then 
washed three times for 5 min each using TBS-T before addition of secondary antibody 
for I h at room temperature (goat anti-rabbit-HRP, 1:2000 in blocking solution, 
DAKO). Membranes are washed three times for 5 min each with TBS-T and 
developed using ECL Western Blotting Analysis kit (Amersham Biosciences) and 
visualize on X-OMAT LS film (Kodak). 
2. 
3. 
4. 
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5. Immunofluorescence (Ads or HC-Ad): Cos7 cells were seeded at 50,000 cells per well 
in a 12-well dish, on coverslips, and allowed to adhere overnight. Cells were infected 
with Ad-IL4-TRE-IL-13.PE and Ad-TetON and were incubated with or without 1 
μg/ml DOX for 48 h. After fixing as described above, transgenes were detected by 
immunofluorescence using primary antibodies against IL-4 or IL-13 (R&D Systems) 
in combination with a primary antibody against PE toxin developed in our laboratory. 
Wash cells in TBS+0.5% TritonX100 and incubate cells for 1 h with fluorescent 
labeled secondary antibody, protecting from light. Wash in PBS three times. On the 
final wash, add DAPI to visualize nuclei, wash once more with PBS and mount on 
slides with anti-Fade mounting media (ProFade) for analysis using an 
immunofluorescent microscope. Colocalization of the transgenes was observed by 
Confocal microscopy (see Fig. 5). Note that transgene expression was only observed 
when cells were incubated in the presence of Dox. 
Viability assay (MTS): Cell viability was determined by the 3-(4,5-dimethylthiazol-2- 
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS) assay. 
Cos7, IN859, and U251 cells were seeded at 5000 cells per well in a 96-well dish and 
infected with Ad-IL4-TRE-IL-13.PE and Ad-TetON. Cells were incubated with or 
without 1 μg/ml DOX for 48 h. Twenty microliters of reaction solution containing 
MTS (final concentration 333 μg/ml) and an electron coupling reagent (phenazine 
ethosulfate, final concentration 25 μM) were added to each well containing 100 μl of 
culture medium. After 3 h at 37°C. the OD was read in a micropore spectrophotometer 
at a wavelength of 495 nm. The quantity of formazan product is directly proportional 
to the number of living cells in culture. Ad-IL4-TRE-IL13.PE was designed to 
produce PE toxin conjugated to a variant of IL-13 that binds specifically with the 
IL-13α2R receptor found almost exclusively on glioma cells. Cell viability was 
reduced 70% when the U251 and IN859 human glioma cells expressing the 
IL-13α2R (see Fig. 6) were incubated in the presence of Ad-IL4 TRE-IL13.PE in the 
“ON” state (Dox+) but remained unaffected in the “OFF” state, indicating that the 
expression of the chimeric toxin can be tightly regulated. Ad-IL4-TRE-IL13-PE did 
not affect the viability of COS-7 cells (African Green Monkey SV40-transfected 
kidney fibroblast cell line), which do not express the IL13alpha2 receptor (see Fig. 
5). These results suggest that the cytotoxic effect of the chimeric is specific to glioma 
cells. The control vector Ad-IL4-TRE-IL13 did not affect the viability of human 
glioma cells or COS-7, neither in the presence nor in the absence of Dox. 
6. 
3.6. Confirming Inducible Gene Expression in Vivo 
Here we describe the detection of transgene expression in vivo using immunohistochemistry 
after stereotactic injection of inducible adenoviral vectors into the brain striatum. However, 
these methods can be applied to immunohistochemical analysis of any tissue of interest. 
1. Male Fisher 344 rats of 200–250 g of body weight (Harlem Sprague Dawley Inc.) 
were used for in vivo HC-Ad-mediated gene delivery. Rats were given drinking water 
containing 2.0 mg/ml Dox (Sigma) and 1% sucrose or 1% sucrose alone 24 h before 
brain surgery and HC-Ad delivery. 
On the day of surgery, the animal was anesthetized with ketamine and medatomadine, 
the head area was shaved, prepared with betadyne, and placed in a stereotactic frame 
ready for surgery. A total of 1 × 109 vp of HC-Ad-mTetON-Flt3L, was injected in 
the rat striatum [coordinates from bregma (the contact between sagittal and coronal 
sutures) were the following: anterior, +1.0 mm; lateral, +3.0 mm; ventral. +4.0 mm] 
using a 10-μl Hamilton syringe (47). A total volume of 3 μl of HC-Ad vector diluted 
in 0.9% w/v saline per animal was injected in the striatum over a 5-min period. 
Subsequent to vector injection, the needle was left in place for a further 2 min before 
2. 
Curtin et al. Page 13 
careful needle retraction. As a negative control, one group of rats received 3-μl saline 
injections. 
3. After postoperative surgery, both untreated and treated animals received drinking 
water containing Dox and 1% sucrose, 1% sucrose alone, or water alone during the 
required times, and drinking water was changed daily. 
After 6 days, animals were then sacrificed and brains were perfused with 
approximately 200 ml oxygenated Tyrode's solution by means of trans-cardial 
perfusion. Rats were next perfused with 250 ml of 4% paraformaldehyde, pH 7.4 (4% 
PFA), fixative, and brains were stored postfixed in 4% PFA for 3 days at 4°C followed 
by 3 days of washing in PBS containing 0.1% sodium azide. 
Brains were serial sectioned using a vibratome to obtain 50-μm free-floating sections. 
Sections were stored in PBS containing 0.1% sodium azide at 4°C until ready for use. 
Free-floating brain sections were washed with TBS + 0.5% Triton X-100 followed 
by 0.3% H2O2 incubation to inactivate endogenous peroxidase. Non-specific antibody 
sites and Fc receptors were blocked with 10% normal horse serum for 1 h. 
Sections were incubated for 48 h at room temperature with rabbit polyclonal anti- 
Flt3L primary antibody (1:1000) (generated in our laboratory (15)) diluted in TBS + 
0.5% Triton + 1% horse serum + 0.1% sodium azide. Sections were washed three 
times with TBS plus 0.5% Triton and then incubated with goat anti-rabbit biotinylated 
secondary antibody (1:800) (Dako) for 4 h. The Avidin–biotinylated HRP complex 
was prepared and used for detection using a Vectastain ABC Elite kit (Vector 
Laboratories). 
Following staining with diaminobenzidone (DAB) and glucose oxidase, sections were 
mounted on gelatin-coated glass slides, dehydrated through graded ethanol solutions, 
and carefully covered for microscopy (see Fig. 7). 
4. Notes 
4. 
5. 
6. 
7. 
8. 
1. TRE promoters can be either unidirectional or bidirectional. We have used both 
successfully to produce Ad vectors. Bidirectional promoters allow the simultaneous 
expression of two or more genes. In our experience, expression of two genes from a 
bidirectional promoter is more robust than expression of two genes, separated by an 
IRES, from a unidirectional promoter. We have also used bidirectional TRE promoter 
to simultaneously express four genes upon addition of DOX by using an IRES to 
separate two open reading frames (ORE) on either side of the bidirectional TRE 
promoter. However, if expression of only one transgene is required, then a 
unidirectional promoter is sufficient. 
The transactivator used. rtTA2SM2, is a chimeric protein consisting of the DNA- 
binding domain of the Tet repressor rtTA fused with the transactivation domain of 
VP-16. Point mutations changing the amino acid sequence of rtTA2SM2 have 
improved the induction of gene expression in the presence of DOX (8). 
We have determined that optimal transgene expression can be achieved by generating 
an HC-Ad genome where mCMV-TetON elements are in the opposite direction as 
Tre-transgene elements, and where mCMV and TRE are juxtaposed (see Fig. 4). The 
tTSkid ensures that basal activity of the TRE promoter remains low in the “OFF” 
state, whereas the close association of mCMV transcriptional enhancer elements in 
the mCMV promoter increases the activity of TRE promoter in the “ON” state. 
Different RE require different buffer conditions for optimal activity. Product literature 
accompanying the RF will explain what conditions are required for optimal activity 
2. 
3. 
4. 
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for each enzyme. Usually, two different RE can be used at the same time by selecting 
a buffer with optimal activity for both. However, sometimes, the RE buffers are not 
compatible and lead to suboptimal RE enzymatic activity. In this situation, sequential 
digestion of DNA with the RE may be performed, as long as DNA is precipitated 
from the first RE buffer before starting the second digestion. 
5. Wear protective eye gear (mask or goggles) when cutting DNA bands out of the 
agarose gel. It is also important to note that UV light can cause point mutations, for 
example, by oxidizing Guanine to 8-Oxyguanine that binds with Adenine, not 
Cytosine, resulting in a GC-AT transition. Thus, it is important to limit the time that 
DNA is exposed to UV light. We use a low power UV box and limit DNA exposure 
to the UV light to less than 2 min. 
Bubbles between the gel and the membrane can be removed by first overlaying one 
layer of filter paper on the membrane. Firmly but carefully a 4-ml tube or a 25-ml 
pipette can be rolled over the filter paper from one edge to the opposite edge 2–3 
times. When doing this, it is important to take care not to break the gel or slide the 
membrane off the gel. 
Cloning of HC-Ad vectors requires the manipulation of large plasmids, and 
recombination is often an issue. It is essential to use a recombinase deficient 
Escherichia coli bacterium, we use DH5α. Furthermore, we find that culture of 
bacteria transformed with pSTK120-transgene plasmids is more successful when 
bacteria are grown at 32°C and 160 g. After cloning, plasmids should be checked 
rigorously using REs to confirm that recombination events have not occurred. This 
can identify anomalies that otherwise would not be detected until the HC-Ad vectors 
are produced. In addition, although it has not been specifically mentioned here, DNA 
sequencing to confirm that the gene is present is advisable. 
Considering that during viral replication transgenes are expressed in vector-producing 
cells, production of vectors encoding toxic transgenes is difficult and requires special 
strategies. We have produced adenoviral vectors encoding IL-13-PE toxin in 293 cells 
that are resistant to the toxin. During viral replication, IL-13-PE is expressed in 293 
cells and can inhibit protein synthesis by ADP-ribosylation of EF-2, leading to low 
vector liters. Thus, we used 293 cells stably transfected with pHED-7 (21), which 
encodes the gene for ADP ribosylation-resistant elongating factor-2 (EF-2) from CHO 
cells (22). In these cells. ADP-ribosylating toxins are incapable of EF-2 inactivation; 
thus, they can support the growth of adenoviruses expressing Pseudomonas or 
Diphtheria chimeric toxins, yielding high viral titers. 
Another strategy to block the toxicity of these vectors during adenovirus production 
is to block the intracellular processing of the chimeric toxin. To inhibit protein 
synthesis, IL-13-PE toxin requires furin-mediated proteolytic cleavage that activates 
the exotoxin releasing the catalytic Domain III Thus, adenoviral vectors encoding 
Pseudomonas or Diphtheria chimeric toxins can be produced in wild-type 293 cells 
in the presence of furin inhibitor Decanoyl-RVKR-CMK (5 μM, Calbiochem). 
6. 
7. 
8. 
9. 
10. Transfection of pSTK 120-transgene plasmids into 293Flpe cells can be achieved with 
    high efficiency using the calcium phosphate precipitation method. It is necessary to 
    make new transfection reagents and to avoid repeated freezing and then thawing of 
    the reagents before use. Shorter limes where DNA is added to 2× HBS (e.g., 10 s) 
    work much better than longer times (e.g., 5 min). Polypropylene tubes improve 
    transfection efficiency in our hands compared with polystyrene tubes. We have also 
    tested various commercially available transfection reagents, we find that TransIT 
    (Mirus) and HyFect (Denville) achieve similar high levels of transfection and high- 
    quality viral preparations. Although useful for other applications, we did not have any 
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success using either JetPEI (PolyPlus) or GeneJuice (Novagen) for transfecting HC- 
Ad vectors. Plasmid DNA must be of high quality to rescue HC-Ad vectors. The 
concentration of DNA must be at least 1 μg/ml and the OD260 : OD280 ratio must not 
be above 1.9. 
11. Usually, only one viral band is evident during CsCl purification of HC-Ad viral 
    vectors. This is desirable. Occasionally, we have observed a second viral band present: 
    these preparations are usually of a lower quality when tested in vitro and in vivo. 
12. Real-time qPCR can also be used to quantify the number of viral genomes present. 
    We have found that the information obtained by qPCR is very useful in characterizing 
    HC-Ad preparations. In particular, it allows a sensitive, quantitative measure of the 
    presence of helper virus contamination in the sample. This protocol has already been 
    described in detail (see Puntel et al., (23)). 
13. In our experience, a good-quality HC-Ad vector preparation should meet the 
    following in vitro criteria: 
a. There should be less than 30-fold greater viral particles (measured with 
OD260nm) than viral genomes as determined using qPCR. 
b. There should be less than 10 times as many viral genomes (qPCR) than 
   transgene expressing units (TEU, determined by ICC on Flow cytometry). 
c. Contaminating helper viral particles (measured with plaque forming units 
assay) should be <105 pfu/ml. 
14. Transgene expression in the presence of DOX can be confirmed using a myriad of 
    techniques, the best of which is completely dependent on the transgene that will be 
    detected. We have outlined three such techniques in vitro, ELISA, ICC, and Western 
    blotting that we most commonly use to titrate HC-Ad vectors in vitro. Several other 
    techniques including reverse transcriptase PCR and flow cytometry may also be used 
    and may be preferable depending on the availability of reagents to detect the transgene 
    of interest. 
15. Expression of many transgenes can be confirmed using immunoglobulins purchased 
    from specific companies. However, it may be more desirable to “tag” the transgene 
    (FLAG or Myc tags work well) before cloning it into pmCMV-TetON. Specific, high- 
    affinity immunoglobulins have been developed against these tags improving the 
    sensitivity of the assay for detecting the transgene. 
16. For secretable proteins, e.g., human soluble Flt3L, much of the protein produced will 
    be secreted. Thus, cell culture media from transfecred cells can be used to determine 
    expression of transgene in vitro. 
17. Of the techniques we described to determine whether viral preps induce transgene 
    expression in vitro (i.e., ELISA, ICC, and Western blot), only ICC can give an accurate 
    assessment of the total number of transgene expressing particles in a viral preparation. 
    We have recently attempted to overcome this problem by developing a method of 
    titrating gene expression from Ad vectors using flow cytometry. We have found that 
    this can give a very accurate and comparable assessment of the number of transgene 
    expressing particles in a viral prep compared with ICC. 
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Fig. 1. 
Structure of regulatable first generation (A) and high capacity (B) adenoviral vectors. These 
novel adenoviral vectors express mulL4 and mlL13 or the cytotoxin mulL-13-PE under the 
control of the bidirectional TRE promoter. The TRE promoter is activated by the transactivator 
(TetON) in the presence of the inducer Dox. The expression of the TetON is driven by the 
strong murine CMV promoter from an additional first generation adenovirus that is 
administered with the therapeutic virus, or is included in the high capacity adenovirus, since 
it allows the expression of larger transgenes. 
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Fig. 2. 
A) Linear depiction of the HC-Ad vector encoding the mlL-4 and mlL-13 without or with the 
PE toxin transgene and mCMV driven regulatable TetON switch cassette. The constructs 
indicate the individual components and orientation of the cassettes and their promoters. Some 
restriction enzyme sites are shown with the appropriate size fragments which correspond to 
the sizes indicated in part A. B) Southern blot analysis of IL4 and PE toxin enconded by the 
therapeutic vector. HC-Ad plasmids were digested and lanes are as follows: lanes 1 and 8 
Hypperladder; lane 2, pSTK120mA.mlL-4.mlL-13PE Bgl ll digest; lane 3, 
pSTK120mA.mlL-4.mIL-13 Bgl ll digest; lane 4, pSTK120mA Bgl ll digest; lane 5, pLS.IL-4 
Sal l/Eagl digest; lane 6, pLS.IL-13 EcoRV/Hindlll digest; lane 7, pRB 39.1 PE toxin EcoRI/ 
Hindlll digest. Southern blot hybridization was performed with specific probes to IL4 and PE 
toxin. Both of the recombinant HC-Ad vectors, and the control plasmid were positive for mlL4 
(lanes 2, 3 and 5); the hybridization for PE toxin was positive only in the therapeutic HC-Ad 
vector and in the control plasmid (lanes 2 and 7). 
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Fig. 3. 
Construction of High-Capacity adenoviral vectors (HC-Ad). A. HC-Ad vectors are rescued by 
transfecting 293 cells expressing FLPe recombinase with linearized pSTK120 plasmids 
containing two adenoviral ITR's, a packaging signal, an expression cassetle (Tet ON regulated), 
and inert stuffer DNA. The cells are infected with FL helper virus containing two loxP sites 
flanking its packaging signal 24 hours later (MOI 5 pfer per cell). The cells are harvested and 
lysed 48 hours later. B. The HC-Ad vectors are amplified on 293-FLPe cells by 5–7 more serial 
passages of 10% of the cell lysate from the previous passage, the last of which onto one 150 
mm dish with the addition of fresh FL helper virus (MOI 1). The tites of the HC-Ad vectors 
increases with each serial passage, eventually surpassing the titer of the FL helper which is not 
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efficiently packaged due to the excision of its packaging signal. C. During scale up, 100% of 
P6 lysate is co-infected with fresh FL helper virus into 30 150 mm dishes containing 293-FLPe 
cells. Cells are harvested 48 hours later. D. Cells are lysed with 5% deoxycholate and DNaseI 
and HC-Ad vectors are purified over three CsCl step gradients. The vectors are dialyzed against 
three changes of dialysis buffer supplemented with 10% glycerol, aliquoted, and stored at −80° 
C. 
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Fig. 4. 
Regulated expression of Flt3L from the high capacity adenoviral vetor(HC-Ad-mTetON- 
Flt3L) in human and murine glioma cells. Established human glioma cell lines (U251, U87), 
cultures from human glioma biopsies (IN859, IN 2045), rat (CNS-I), and mouse (GL26) glioma 
cells were infected with HC-Ad vector encoding Flt3L under the control of a TetON system 
driven by the murine CMV promoter (HC-Ad-mTetON-Flt3L) for 72 h in the presence or 
absence of the inducer doxycyline (Dox, 1 μg/ml). Transgene expression was determined by 
ELISA and immunocytochemistry (ICC). 
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Fig. 5. 
mlL-13-PE toxin expression from the therapeutic (Ad-IL4-TRE-IL13.PE) adenoviral vector 
in COS-7 cells. A. COS-7 cells were infected with the therapeutic adenoviral vector (Ad-IL4- 
TRE-IL13. PE) that express mulL4 and mlL13 or the cytotoxin mulL-13-PE under the control 
of the bidirectional TRE promoter, which is activated by the transactivator (TetON) in the 
presence of the inducer Dox. Microphotographs show the regulated expression of the mlL-13- 
PE toxin, as determined by immunocytochemistry in the presence (Dox+) or absence (Dox−) 
of the inducer. B. COS-7 cells (were infected with control (Ad-IL4-TRE-IL13) and therapeutic 
(Ad-IL4-TRE-IL13.PE) adenoviral vectors. Upper panels: Cell viability was determined by 
MTS assay. Lower panels: IL-13alpha2R expression was determined by 
immunocytochemistry. Nuclei were stained with DAPI. Note that the therapeutic Ad-IL4- 
TRE-IL13.PE exert its cytotoxic effect only in cells expressing the glioma-restricted IL-I 
3alpha2R. 
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Fig. 6. 
mlL-13-PE toxin induces cell death in glioma cells. A. IN859 and B. U251 human glioma cells 
were infected with the therapeutic adenoviral vector (Ad-IL4-TRE-IL13.PE) or control vector 
Ad-IL4- TRE-IL13. Upper panels: Cell viability was determined by MTS assay. Lower panels: 
IL-13alpha2R expression was determined by immunocytochemistry. Nuclei were stained with 
DAPI. Note that the therapeutic Ad-IL4-TRE-IL13.PE exert its cytotoxic effect only in cells 
expressing the glioma-restricted IL- 13alpha2R. 
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Fig. 7. 
Inducible Flt3L expression in vivo. Male Lewis rats fed Dox supplemented chow 24 h before 
injection of 1×109 vp HC-Ad-mCMV-TetON-Flt3L into the brain striatum. After 7 days, rats 
were euthanized, fixed with PFA and coronal sections of the brain were taken using a vibratome 
(Leica). Brain sections were stained with rabbit anti-Flt3L as outlined in the materials and 
methods section and images were visualized on a Zeiss Axioplan 2 microscope under 1.25× n 
d 40× objectives. Expression of Flt3L was not observed in rats fed normal chow without Dox 
(not shown). 
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Table 1 
Plasmid Sources and Function 
Name Function Reference 
pΔE1sp1A A first generation shuttle plasmid containing Xba1, 
Hind3 and Sal1 (among others) in the multiple cloning 
site. 
A first generation shuttle vector containing the mCMV 
promoter and a pA signal sequence. Sal 1 is used for 
cloning transgenes downstream of the mCMV promoter 
and upstream of the pA. 
An intermediate plasmid in the cloning of the TetON 
cassette, it is a modified pIRES plasmid containing the 
tTSkid-pA sequence downstream of the IRES. 
This plasmid contains the tTSkid repressor and 
polyadenylation (pA) signal flanked by Xba1 and 
Hind3. 
Cloning plasmid containing the Internal Ribosome 
Entry Site (IRES) from the encephalomyocarditis virus. 
This plasmid carries the rtTA2S-M2 Tet-sensitive 
transactivator gene flanked by EcoR1 and BamH1. 
8200 bp plasmid based on pIRES containing rtTA2S M2 
upstream and tTSkid immediately downstream of the 
IRES sequence (i.e., the TetON cassette) flanked by 
Xho1 and Sal1. 
Modified cloning plasmid (original from Clontech) with 
a multiple cloning site that contains Bgl2, Hind3 and 
EcoR1 among others. 
pSP72-Bgl2 containing the mCMV promoter and pA 
sequence (from pAL120). 
Intermediate plasmid containing the TetON cassette 
regulated by the mCMV promoter. The entire cassette 
is flanked on both ends by Bgl2. 
Intermediate vector based on the bluescript 2 SK+ 
plasmid. 
pBlueScript based vector containing the TetON cassette 
and also containing the Tet-sensitive promoter TRE 
upstream of a multiple cloning site (Age1, Afl2, Swa1, 
Bel1) and pA. 
Adaptor plasmid generated in our laboratory containing 
two copies each of the Age1, Afl2, Swa1, and Bcl1 
restriction endonuclease sites. By cloning transgene 
through this vector, these rare restriction sites can be 
used to clone directly into pmCMV-TetON. 
Plasmid used to generate high capacity adenoviral 
vectors. Plasmid only shares long terminal repeat (LTR) 
and packaging (Ψ) sequences of wild type Adenovirus. 
Several variants have been created, e.g., pSTK120.1, 
pSTK120.2, and pSTK120.3. 
Microbix Biosystems 
pAL120 Generated in our laboratory 
(24) 
pIRES-tTSKid-pA Generated in our laboratory 
(2) 
H. Bujard at ZMBH, 
Germany (8) 
Clontech 
H. Bujard at ZMBH, 
Germany (8) 
Generated in our laboratory 
(2) 
pUHS 6-1 
pIRES 
pUHrT 62-1 
prtTA2S M2-IRES-tTSkid-pA 
pSP72-Bgl2 Generated in our laboratory 
(2). 
Generated in our laboratory 
(2). 
Generated in our laboratory 
(2) 
Generated in our laboratory 
(unpublished) 
Generated in our laboratory 
(unpublished) 
pSP72-mCMV 
pSP72[mCMV-rtTA2SM2-IRES-tTSkid-pA] 
pBS2SK+ [Tre-MCS-pA]-Kana 
pmCMV-TetON 
pSP72Bgl2-MCS Generated in our laboratory 
(unpublished) 
pSTK120 Generated by S. Kochanek 
(25) 
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Table 2 
HC-Ad Plasmids and Predicted Cloning Capacities for Transgene Cassettes 
Plasmid Cloning capacity (Kb) Restriction sites for cloning in transgene cassette 
pSTK120 
pSTK120.1 
pSTK120.2 
pSTK120.3 
0–7 
2–10 
4–13 
8–18 
Eag1 
Nhe1, Eag1 
Nhe1, Eag1, Nar1 
Nhe1, Eag1, Nar1, Ncol 
